BioXcel Files Chapter 11, Teva Stalking Horse Bid at $57.5M Plus Milestones
BTAI is trading near its 52-week low of $0.7 (33% below the low).
Summary
BioXcel Therapeutics filed for Chapter 11 bankruptcy and entered a stalking horse asset purchase agreement with Teva Pharmaceuticals for $57.5 million upfront plus up to $87.5 million in milestones. DIP financing of up to $19 million new money from Oaktree and QIA will fund operations during the sale process.
Key Events · Legal and Risk Events · BTAI
-
Chapter 11 Bankruptcy Filed
BioXcel and its subsidiaries filed voluntary Chapter 11 petitions in Delaware on August 27, 2026, continuing operations as debtors-in-possession.
-
Teva Stalking Horse Bid
Teva agreed to acquire substantially all assets for $57.5 million upfront cash, up to $67.5 million in development milestones tied to the IGALMI sNDA, and up to $20 million in commercial milestones.
-
DIP Financing Secured
Oaktree and Qatar Investment Authority will provide up to $19 million in new money term loans (two $9.5 million draws) plus $58.25 million in roll-up loans from prepetition obligations.
-
Chief Restructuring Officer Appointed
Samir Saleem was appointed CRO, reporting to a Strategic Process Committee of the Board to oversee the sale and restructuring process.
Analysis · BTAI · Life Sciences
BioXcel Therapeutics filed for Chapter 11 bankruptcy protection on August 27, 2026, with Teva Pharmaceuticals serving as stalking horse bidder for substantially all assets. The deal provides $57.5 million upfront cash plus up to $87.5 million in contingent milestone payments, while DIP financing from Oaktree and Qatar Investment Authority provides up to $19 million in new money and $58.25 million in roll-up loans. This is a thesis-altering event: the company's future is now fundamentally different, with equity holders facing significant uncertainty about recovery value in the bankruptcy process.
At the time of this filing, BTAI was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $0.70 to $5.19. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.